UPDATE: Raymond James Upgrades Jounce Therapeutics (JNCE) to Outperform
Tweet Send to a Friend
(Updated - September 14, 2021 3:55 AM EDT)
Raymond James analyst Steven Seedhouse upgraded Jounce Therapeutics (NASDAQ: JNCE) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Raymond James analyst Steven Seedhouse upgraded Jounce Therapeutics (NASDAQ: JNCE) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
